



**ASX Announcement**

**4 March 2024**

## **Change of Company Secretary**

Atomo Diagnostics Limited (ASX: AT1) (**Atomo** or the **Company**) wishes to advise in accordance with ASX Listing Rule 3.16.1 that Ms Sally McDow of BoardRoom Pty Limited has been appointed Company Secretary, with effect from 5 March 2024. For the purposes of ASX Listing Rule 12.6, Ms Sally McDow will also be the primary person responsible for communications between the Company and the ASX.

Ms Maria Clemente of BoardRoom Pty Limited has notified the Board of her resignation as Company Secretary with effect from 5 March 2024. Atomo thanks Ms Clemente for her support of the Board during her time with the Company.

### **For more information:**

#### **John Kelly**

MD & CEO, Atomo Diagnostics Limited

[john.kelly@atomodiagnositics.com](mailto:john.kelly@atomodiagnositics.com)

+61 401 922 279

*This announcement was authorised by the Board of Atomo Diagnostics Limited.*

### **About Atomo**

Atomo is an Australian headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.

Atomo's unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including COVID-19, HIV, viral vs bacterial differentiation and female health.

See more at [www.atomodiagnositics.com](http://www.atomodiagnositics.com)